The new chief executive of Germany’s Stada, who took over after his predecessor Harmut Retzlaff left for health reasons, has stripped Retzlaff’s son Steffen of some responsibilities and has fired the former CEO’s external advisors, taking a firmer grip of the maker of generic drugs and consumer care products.
Stada earlier this month said its long-time chief executive Harmut Retzlaff would temporarily leave office for health reasons and that fellow executive board member Matthias Wiedenfels would take over as CEO.
Steffen Retzlaff will no longer be in charge of Stada subsidiaries Hemopharm GmbH and Stadavita GmbH and will focus on his responsibility for the regions Asia and Pacific, Middle East and North Africa, Wiedenfels told staff in a letter dated June 20, which was obtained by Reuters.
A company spokesman confirmed the contents of the letter.
External advisors which have been acting as “Senior Advisors to the CEO” have been relieved of their duties, Wiedenfels told staff in the letter.
By Alexander Huebner
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.